# Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

> **NCT01167816** · PHASE1 · TERMINATED · sponsor: **University of Oklahoma** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Vidaza

## Key facts

- **NCT ID:** NCT01167816
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The study was terminated as the Prinicipal Investigator left the site- all previous subjects enrolled are deceased
- **Last updated:** 2014-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01167816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01167816, "Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01167816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*